All In Biotech

Drug Trial Radar · NCT07309614

A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Jan 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Université de SherbrookeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; University of Oxford; The University of Western Australia; Regeneron Pharmaceuticals; Fonds de la Recherche en Santé du Québec; Association Pulmonaire du Quebec
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened significantly and caused lung damage. This study explores whether treating high-risk patients earlier could prevent asthma attacks and lung function decline, potentially achieving remission before permanent damage occurs. The study is looking for adults aged 18-79 with moderate asthma who have had at least one asthma attack requiring steroid pills in the past 2 years, use medium or high-dose inhaled steroids regularly, have high levels of inflammation markers in their blood and breath tests, but don't yet meet criteria for severe asthma requiring biologic therapy. Participants receive either dupilumab or placebo injections every 2 weeks for one year, alongside their regular asthma medications. They attend clinic visits every 3 months for breathing tests, questionnaires, and safety monitoring. Neither participants nor doctors know who receives the real medication until the study ends. The goal is to learn whether early treatment with dupilumab helps more people achieve complete asthma control compared to standard care alone, potentially changing how asthma is treated from "waiting until severe" to "preventing severe disease." The study runs in Canada, the United Kingdom, and Australia, involving 150 participants

Conditions

  • Asthma Control

Interventions

  • Dupilumab Prefilled SyringeDrug

    Dupilumab 400mg subcut x1 followed by 200mg subcut every 2 weeks

  • Placebo InjectionDrug

    Volume-matched placebo injected subcut every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Win ratio based on remission criteriaTime frame: Week 4 to Week 56 (except FEV1 change: Week 0 values serve as baseline)

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Not yet recruiting

  • Institut universitaire de cardiologie et de pneumologie de Québec

    Québec, Quebec, Canada · Recruiting

  • CIUSSS de l'Estrie- CHUS

    Sherbrooke, Quebec, Canada · Recruiting

  • Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital

    Oxford, Oxfordshire, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.